gamma secretase modulator 3

Gamma-secretase modulator 3 [gamma-secretase modulator] is a compound that regulates gamma-secretase activity.

γ-Secretase modulator 13 is a γ-secretase modulator (GSMs) that inhibits the production of amyloid β-peptide Aβ42 and can be used to study Alzheimer's disease and tumors.

gamma-secretase modulator 1 is a modulator of γ secretase and can be used in studies about the treatment of Alzheimer's disease.

CB2R FAAH modulator-3 (compound 27) is a modulator targeting CB2R and FAAH, acting as a CB2R agonist with a Ki value of 20.1 nM and a CB1R agonist with a Ki value of 67.6 nM, while inhibiting FAAH with an IC50 value of 3.4 μM. This compound has research value in cancer, neurodegenerative disease-related inflammatory cascades, and COVID-19 infection.

IL-17 modulator 3 (US20200247785A1) is a chemical compound that acts as an IL-17 modulator. It has potential applications in researching inflammation, cancer, and autoimmune diseases.

γ-Secretase modulator 4 is a potent γ-secretase modulator that reduces Aβ42 levels with IC50s of 0.017 μM in mice and 0.014 μM in humans.

NMDA receptor modulator 3 (Compound 99) is a potent NMDA receptor modulator useful in neurological disorder research [1].

PCSK9 modulator-3 (Compound 13) is a potent PCSK9 modulator with an EC50 value of 2.46 nM, showing potential in hyperlipidemia research. PCSK9 is a newly established target for lowering low-density lipoprotein cholesterol (LDL-C) [1].

IL-17A Modulator-3, an inhibitor of IL-17A/A, exhibits an IC 50 value of less than 10 μM. It is utilized in research related to inflammation, cancer, and autoimmune diseases.

γ-Secretase modulator 12 (Compound 1a) is a selective compound that effectively reduces amyloid-β42 (Aβ42) levels with an IC50 of 0.39 μM, specifically designed for Alzheimer's disease research. Notably, γ-Secretase modulator 12 exhibits a favorable brain plasma ratio (Kp, brain = 0.72) in mice [1].

Kv3 modulator 3 is a selective modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels .has analgesic activity for use in the prophylaxis o or treatment of pain.

Glucocorticoid receptor modulator3 (Payload 6) is a thioester-based modulator of the glucocorticoid receptor, exhibiting a potent IC50 value of 0.6 nM. This compound is deactivated through rapid hepatic metabolism, minimizing systemic exposure of its unconjugated active payload. Glucocorticoid receptor modulator3 is suitable for development in antibody-drug conjugates (ADCs) targeted at autoimmune diseases.

Progranulin modulator-3 (compd C40) is an orally active inducer of the precursor granulin protein (PGRN) that can penetrate the blood-brain barrier. It is utilized in neurological research.

γ-Secretase modulator 10 (GSM-10) is a novel compound that modulates γ-secretase activity.

P2X2/3 Modulator-1 (Compound 46) serves as a modulator of P2X2/3 receptors and has applications in researching pain, central nervous system disorders, and inflammation [1].

Gamma-secretase inhibitor-1 is a gamma-secretase modulator valuable for Alzheimer's disease [1].

γ-Secretase Modulator 14, a γ-secretase modulator, shows potential for use in Alzheimer's disease (AD) research (WO2013010904A1; compound 42) [1].

Gamma-secretase modulator 5 (compound 22d) is a gamma-secretase modulator (GSM) that crosses the blood-brain barrier and inhibits the production of the aggregated amyloid β peptide Aβ42 (IC50: 60 nM). This compound is valuable for studying Alzheimer's disease.

β-Catenin modulator-3 (compound IIa-112), an oxazole and thiazole-based chemical entity, serves as a potent and selective modulator of β-Catenin [1].

Gamma-secretase modulator 2 is a potent, selective compound for the treatment of Alzheimer's disease, specifically designed to modulate γ-secretase activity. This modulation selectively attenuates the production of Aβ(1-42), addressing diseases associated with Aβ deposition in the brain, particularly Alzheimer's disease.

gamma-Secretase Modulators serves as a useful treatment for Alzheimer's disease by inhibiting the production of Amyloid-β. Specifically, it acts as a gamma-Secretase Modulators with an IC50 value.

RNA Splicing Modulator 3 (Compound 236) is an effective RNA splicing modulator, exhibiting an AC50 value of less than 100 nM [1].

γ-Secretase modulator 11 hydrochloride is a potent, orally active γ-secretase modulator (IC50: 0.029 μM). γ-Secretase modulator 11 hydrochloride significantly reduces brain Aβ42 levels and rescues the cognitive deficits exhibited by AD model mice. γ-Secretase modulator 11 hydrochloride has shown research potential in Alzheimer's disease.

P-gp modulator 3 (Compound 37) is a potent, competitive metabotropic P-glycoprotein (P-gp) modulator.

RORγt modulator 3 is a modulator of retinol-related orphan receptor γt (RORγt) and can be used to study RORγt-mediated diseases such as pain, COPD, inflammation, asthma, colitis, multiple sclerosis, rheumatoid arthritis, psoriasis, neurodegenerative diseases and cancer.

5-{8-[(3,4'-Difluoro[1,1'-biphenyl]-4-yl)methoxy]-2-methylimidazo[1,2-a]pyridin-3-yl}-N-methylpyridine-2-carboxamide (1o) exhibited high in vitro potency and brain exposure, significantly reduced brain Aβ42 levels, showed no inhibitory effect on cytochrome p450 enzymes, and demonstrated excellent anti-cognitive deficits in AD model mice.

STING modulator-3 is a STING inhibitor with a Ki value of 43.1 nM in scintillation proximity assays, specifically targeting R232 STING. It does not affect IRF-3 activation or TNF-β induction in THP-1 cells.

CB1R Allosteric modulator 3 is a potent CB1R modulator that inhibits cAMP and β-Arrestin and can be used for the study of obesity and nicotine addiction.

Nur77 modulator 3 (9e) binds to Nur77 and inhibits TGF-β1-induced α-SMA and COLA1 expression in a Nur77-dependent manner. It induces Nur77 expression and enhances autophagic flux by inhibiting the mTORC1 signaling pathway in vitro and in vivo. Nur77 modulator 3 blocks the progression of hepatic fibrosis [1].